genmab.com (GMAB) - חוב להון עצמי

The current total debt leverage level demonstrates financial stability, while the 0.86 metric confirms the current level of indebtedness. This is critical given the dependence on a single patent and potential clinical trial failures. Meanwhile, Genmab A/S develops high-precision antibodies for cancer therapy, adhering to trial ethics and environmental waste disposal regulations.

The total debt-to-equity ratio measures the proportion of borrowed funds in the asset financing structure relative to equity. Investors utilize this metric to assess financial stability and the extent of a business's dependence on external creditors. Analyzing the total debt/equity chart allows for the identification of critical liquidity imbalances. For Genmab A/S (GMAB), low leverage confirms the effectiveness of a model based on royalties from Darzalex sales. Such a structure minimizes bankruptcy risks during the development of new drugs.